VILMA: Therapeutic Results in Acute Mieloblastic Leukemia in Patients Older Than 60 Years
NCT02606825 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3910
Last updated 2020-05-27
Summary
This is a retrospective study to analyze the therapeutic results and clinical evolution all patients diagnosed with AML and aged ≥ 60años or not candidates for chemotherapy intensive, treated according to the different schemes available, including supportive care or palliative.
Conditions
Interventions
- OTHER
-
Registry of AML patients > 60 years
Sponsors & Collaborators
-
PETHEMA Foundation
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2015-07-31
- Primary Completion
- 2018-02-15
- Completion
- 2018-02-15
Countries
- Spain
Study Locations
More Related Trials
-
Elderly Patients With Acute Myeloid Leukemia (AML), Maintenance Phase After Complete Remission (CR)
NCT01301820 ·Status: COMPLETED ·Phase: PHASE2
-
Randomised Prospective Comparison of the NMA Allograft and the Traditional Allograft in Acute Myeloid Leukaemia
NCT00224614 ·Status: UNKNOWN ·Phase: PHASE3
-
Master Framework For Relapse or Refractory Acute Myeloid Leukemia
NCT06459024 ·Status: RECRUITING
-
Epidemiological Study of a Prospective Cohort of Patients Aged 60 and Over Managed for Acute Myeloid Leukemia (AML) and Receiving Intensive Induction Therapy
NCT06891144 ·Status: RECRUITING
-
Combination of HMA and Venetoclax With Posaconazole in Patients With Acute Myeloid Leukemia: A Study of Plasma Concentrations
NCT07254611 ·Status: COMPLETED
-
Study With Temsirolimus Added to Standard Chemotherapy for Patients Over 60 Years With Acute Myeloblastic Leukemia
NCT01611116 ·Status: COMPLETED ·Phase: PHASE2
-
A Randomized Study of Post-Remission Therapy in Elderly Patients With Acute Myelogenous Leukemia.
NCT00363025 ·Status: TERMINATED ·Phase: PHASE3
-
Survival in Patients Older Than 60 Years With Newly Diagnosed AML in Spain
NCT03435341 ·Status: COMPLETED
-
Optimizing Induction Chemotherapy Regimens for ND Elderly AML Patients Who Are Eligible for Intense Chemotherapy
NCT06066242 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
NCT06317649 ·Status: RECRUITING ·Phase: PHASE2
-
PETHEMA LAL-07FRAIL: All Treatment In Fragile Patients Ph' Negative Over 55 Years
NCT01358201 ·Status: UNKNOWN ·Phase: PHASE4
-
Dynamics of Resistance Emergence to Azacitidine-based Therapies in Acute Myeloid Leukemia
NCT06225128 ·Status: RECRUITING
-
Venetoclax + Cytarabine Versus Idarubicin + Cytarabine : Efficacity Assessment as Post-remission Therapy to Elderly Patients With Acute Myeloid Leukemia in First Remission
NCT04968015 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML)
NCT01074047 ·Status: COMPLETED ·Phase: PHASE3
-
Volasertib in Combination With Low-dose Cytarabine in Patients Aged 65 Years and Above With Previously Untreated Acute Myeloid Leukaemia, Who Are Ineligible for Intensive Remission Induction Therapy (POLO-AML-2)
NCT01721876 ·Status: COMPLETED ·Phase: PHASE3
-
TMLI Plus Chemotherapy in High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia
NCT06598969 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Treatment of Acute Lymphoblastic Leukemia HIGH RISK BCR / ABL NEGATIVE IN ADULTS
NCT01540812 ·Status: COMPLETED
-
Therapy of Acute Myeloid Leukemia in Patients Over the Age of 60 : DA Versus Mitoxantrone With Intermittent AraC
NCT00180167 ·Status: COMPLETED ·Phase: PHASE4
-
PETHEMA LAL-RI/96: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia
NCT00494897 ·Status: COMPLETED ·Phase: PHASE4
-
Refining the Role of Mid-induction Bone Marrow Biopsy in Acute Myeloid Leukemia: A Pilot Study
NCT06323590 ·Status: ACTIVE_NOT_RECRUITING
-
IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia.
NCT06713837 ·Status: RECRUITING ·Phase: PHASE3
-
Diagnostic Platform to Perform Centralized and Standardized Rapid Molecular Diagnosis by Next Generation Sequencing (NGS) in Patients Diagnosed With Acute Myeloid Leukemia.
NCT03311815 ·Status: COMPLETED
-
Molecular Subtype Combined with Early Minimal Residual Disease to Optimize the Treatment of Newly Diagnosed Acute Myeloid Leukemia
NCT06652685 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Prospective Non-interventional Study of Adult Patients With Acute Myeloid Leukemia (AML)
NCT04777916 ·Status: RECRUITING
-
Azacitidine + Lenalidomide Combo in the Elderly With Previously Treated AML & High-Risk MDS
NCT01442714 ·Status: TERMINATED ·Phase: PHASE2